Literature DB >> 29197940

Thymoquinone Augments Cisplatin-Induced Apoptosis on Esophageal Carcinoma Through Mitigating the Activation of JAK2/STAT3 Pathway.

Xue Hu1,2, Jingjing Ma1, Vikash Vikash1, Jiao Li1, Dandan Wu1, Ya Liu1, Jixiang Zhang1, Weiguo Dong3.   

Abstract

BACKGROUND: Thymoquinone (TQ) is the major constituent of Nigella sativa seed and has shown biological activity in various human carcinomas. However, few studies have reported its effect on esophageal carcinoma (EC). AIMS: To explore the chemosensitive effect and mechanism of TQ in augmentation of cisplatin (DDP)-induced apoptosis of EC, both in vitro and in vivo.
METHODS: The viability and apoptosis of esophageal carcinoma cells were detected by the Cell Counting Kit-8 assay, flow cytometry, and Hoechst 33258 staining. The expression levels of JAK2, p-JAK2, STAT3, p-STAT3, Bax, Bcl-2, Cyclin D1, Survivin, and caspase-3, 7, 9 were evaluated by western blot analysis. The histological changes were examined by TUNEL technique and immunohistochemical analysis.
RESULTS: TQ enhanced the proapoptotic effect of DDP in human esophageal carcinoma cell line Eca-109, while blocking the activation of JAK2/STAT3 signaling pathway. The apoptosis of esophageal carcinoma cells was induced via blocking the activation of JAK2/STAT3 by using a molecular inhibitor (WP1066). Consistent with the in vivo and in vitro results, TQ increased cellular apoptosis and enriched the chemosensitivity of DDP.
CONCLUSIONS: TQ along with DDP may regulate the progression of EC and has potential to be a chemotherapeutic agent in EC.

Entities:  

Keywords:  Apoptosis; Esophageal carcinoma; STAT3; Thymoquinone; WP1066

Mesh:

Substances:

Year:  2017        PMID: 29197940     DOI: 10.1007/s10620-017-4856-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  The STAT3 oncogene as a predictive marker of drug resistance.

Authors:  Benjamin Barré; Arnaud Vigneron; Neil Perkins; Igor B Roninson; Erick Gamelin; Olivier Coqueret
Journal:  Trends Mol Med       Date:  2006-11-21       Impact factor: 11.951

2.  Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway.

Authors:  Chern Chiuh Woo; Ser Yue Loo; Veronica Gee; Chun Wei Yap; Gautam Sethi; Alan Prem Kumar; Kwong Huat Benny Tan
Journal:  Biochem Pharmacol       Date:  2011-06-14       Impact factor: 5.858

3.  Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo.

Authors:  Xiaofei Lei; Xiaoguang Lv; Meng Liu; Zirong Yang; Mengyao Ji; Xufeng Guo; Weiguo Dong
Journal:  Biochem Biophys Res Commun       Date:  2011-12-20       Impact factor: 3.575

4.  Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo.

Authors:  Samir Attoub; Olivier Sperandio; Haider Raza; Kholoud Arafat; Suhail Al-Salam; Mahmood Ahmed Al Sultan; Maha Al Safi; Takashi Takahashi; Abdu Adem
Journal:  Fundam Clin Pharmacol       Date:  2012-07-13       Impact factor: 2.748

5.  Global incidence of oesophageal cancer by histological subtype in 2012.

Authors:  Melina Arnold; Isabelle Soerjomataram; Jacques Ferlay; David Forman
Journal:  Gut       Date:  2014-10-15       Impact factor: 23.059

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L.

Authors:  D R Worthen; O A Ghosheh; P A Crooks
Journal:  Anticancer Res       Date:  1998 May-Jun       Impact factor: 2.480

8.  Thymoquinone-induced reactive oxygen species causes apoptosis of chondrocytes via PI3K/Akt and p38kinase pathway.

Authors:  Seon-Mi Yu; Song-Ja Kim
Journal:  Exp Biol Med (Maywood)       Date:  2013-06-20

9.  Thymoquinone: An IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities.

Authors:  Muhammad Jahangir Hossen; Woo Seok Yang; Daewon Kim; Adithan Aravinthan; Jong-Hoon Kim; Jae Youl Cho
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

10.  ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway.

Authors:  Jinqiong Jiang; Yiping Liu; Youhong Tang; Li Li; Ruolan Zeng; Shan Zeng; Meizuo Zhong
Journal:  Onco Targets Ther       Date:  2016-08-29       Impact factor: 4.147

View more
  5 in total

Review 1.  Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone.

Authors:  Ammad Ahmad Farooqi; Rukset Attar; Baojun Xu
Journal:  Int J Mol Sci       Date:  2022-06-05       Impact factor: 6.208

Review 2.  Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex.

Authors:  Omeima Abdullah; Ziad Omran; Salman Hosawi; Ali Hamiche; Christian Bronner; Mahmoud Alhosin
Journal:  Genes (Basel)       Date:  2021-04-22       Impact factor: 4.096

3.  Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma.

Authors:  Dan-Dan Xu; Men Ding; Pan Tong; Yan-Yun Chong; Wei-Yu Gu; Yang Li; Xin-Jiang Fang; Ning Li
Journal:  Oncol Rep       Date:  2020-07-07       Impact factor: 3.906

4.  Sinomenine sensitizes human gastric cancer cells to cisplatin through negative regulation of PI3K/AKT/Wnt signaling pathway.

Authors:  Ying Liu; Changqing Liu; Ting Tan; Shang Li; Shunyu Tang; Xingyin Chen
Journal:  Anticancer Drugs       Date:  2019-11       Impact factor: 2.248

5.  Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review).

Authors:  Rui-Jie Ma; Chao Ma; Kang Hu; Meng-Meng Zhao; Nan Zhang; Zhi-Gang Sun
Journal:  Int J Oncol       Date:  2022-07-20       Impact factor: 5.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.